Michaela Viktorinová

Clinical psychologist and researcher

Data updated

Papers

6 publications

Trials

0 clinical trials

Links

Research Footprint

Michaela Viktorinová appears in 6 tracked papers (2018–2026), most studied alongside Psilocybin and Placebo, across Healthy Volunteers, Neuroimaging & Brain Measures and Schizophrenia.

Most-cited paper: Psilocybin disrupts sensory and higher order cognitive processing but not pre-attentive cognitive processing-study on P300 and mismatch negativity in healthy volunteers (48 citations).

Frequent co-authors: Tomáš Páleníček, František Tylš and Martin Brunovský.

Background & Research

Michaela Viktorinová studied psychology at Charles University in Prague and completed an MSc program in psychodynamic developmental neuroscience at University College London–Yale Child Study Center. She worked for years at the National Institute of Mental Health in the Czech Republic, where she participated in clinical research on psychedelics, including psilocybin for depression and MDMA-assisted psychotherapy for PTSD. She is currently listed as a clinical psychologist at KAPPA and is active in psychotherapy and neuroscience-related work.

Key Impact

She is a coauthor on multiple psilocybin studies spanning cognition, EEG, phenomenology, sleep, and perceptual effects, making her a notable contributor to Czech psychedelic science.

6

Research Papers

View publications →

0

Clinical Trials

Explore trials →

Collaboration Network

7 collaborators· click a node to visit their profile

Full network →